(Namita Pradhan, Intern Journalist) Cipla, the pharmaceutical firm is all ready to launch Favipiravir, produced by the Council of Scientific and Industrial Research (CSIR) in a cost-effective way, to treat Covid-19 patients, an official statement was made on Thursday.

Favipiravir was discovered originally by Fuji Pharma in Japan, which has shown promised results in clinical trials to treat Covid-19 patients, especially in mild and moderate cases.

CSIR- Indian Institute of Chemical Technology (CSIT-IICT) created a cost-effective process with using all locally available chemicals to synthesize the Active Pharmaceutical Ingredient and handover its technology to Cipla.

“Cipla has improved its process of the manufacturing facility and approached DCGI( Drug Controller General of India) asking permission to launch the product in India. The DCGI has restricted the emergency use of Flavipiravir in Country, Cipla is all ready to launch its product to help the patients who are suffering from Covid-19” said by the statement.

Director of CSIR-IICR S Chandrasekhar said the technology is very useful and it’s affordable and allows Cipla to produce in more quantities of products in a short time.

About Post Author